Eli Lilly (LLY) and Novo Nordisk (NVO) are intensifying their competition in the burgeoning weight loss drug market, which is projected to reach nearly $100 billion by the end of the decade. Both companies have recently received approvals for oral formulations of their GLP-1 drugs, with Novo’s oral Wegovy already capturing 65% of new prescriptions in its first quarter of commercialization. Meanwhile, Lilly’s Foundayo, which has treated over 20,000 patients since its launch, is expected to gain traction as insurance access improves.
The rapid growth of these oral formulations signals a significant shift in consumer preferences, as patients increasingly favor the convenience of pills over injectables. While Novo currently leads in prescription volume, Lilly’s dual GIP/GLP-1 mechanism may offer a competitive edge in terms of efficacy and patient adherence.
For market professionals, the key takeaway is that both companies stand to benefit from the expanding market for oral weight loss drugs, suggesting potential for sustained growth and investment opportunities in this sector.
Source: fool.com